Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $24.66M rose 191.2% year over year, ahead of the +144.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 17.6% from the prior quarter. Over 3 fiscal years it compounded at +94.7% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +62.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $24.66M+17.6% QoQ
- Last fiscal yearDec 2025
- $38.6M+62.0% YoY
- LTMJun 2026
- $69.2M+144.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +191.2% | -100.0% | -291.2 pp |
| 1 year | +62.0% | -100.0% | -162.0 pp |
| 3-year CAGR | +94.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 38.6M USD
- Year-over-year change
- +62.0%
- 4-year CAGR
- +99.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.6M | +62.0% |
| FY2024 | 2024-12-31 | 23.82M | +66.6% |
| FY2023 | 2023-12-31 | 14.3M | +173.4% |
| FY2022 | 2022-12-31 | 5.23M | +116.3% |
| FY2021 | 2021-12-31 | 2.42M | — |
Selling, General & Admin vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 selling, general & admin of $69.2M is the 3rd highest of the 7 companies compared; the peer median is $33.01M.
- Its year-over-year change of +144.0% is the 2nd highest of 7, against a peer median of +30.6%.
- Over three fiscal years its annual growth of +94.7% compares with a peer median of +22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $376.47M | +23.4% | +19.5% | 57.8% | |
| LTM Jun 2026 | $153.89M | +144.6% | +66.0% | — | |
| LTM Jun 2026 | $69.2M | +144.0% | +94.7% | — | |
| LTM Mar 2026 | $39.04M | +38.9% | +14.7% | 195.2% | |
| LTM Mar 2026 | $26.99M | +11.1% | +24.6% | 82.5% | |
| LTM Mar 2026 | $21.4M | +37.8% | +45.9% | — | |
| LTM Mar 2026 | $9.79M | +21.7% | +16.7% | — | |
| Peer median (excluding MLYS) | $33.01M | +30.6% | +22.0% | 82.5% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M |
| Selling, General & Admin | 2.42M | 5.23M | 14.3M | 23.82M | 38.6M |
| Operating Expenses | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| EBITDA | (19.38M) | (28.12M) | (71.9M) | (177.77M) | (154.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.73M) | (31.48M) | (84.66M) | (192.4M) | (170.6M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.68M | 12.76M | 14.59M | 15.95M |
| Interest Expense | 27K | 1.68M | 0 | 0 | 0 |
| Other Income / Expenses | (683K) | 1.68M | 12.76M | 14.59M | 15.95M |
| Income Before Tax | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| EPS (Diluted) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| Weighted Avg Shares | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
| Weighted Avg Shares (Diluted) | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.